Tuesday, February 16, 2021 6:15:10 AM
AstraZeneca Wins WHO Emergency Listing For COVID-19 Vaccine; Street Sees 31% Upside
https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84342162/astrazeneca-wins-who-emergency-listing-for-covid-1
https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84342162/astrazeneca-wins-who-emergency-listing-for-covid-1
A goal is a dreams deadline...what is your goal?
´¯`·.¸¸.·´¯`·.¸ ><((((((º>
`·.¸¸.·´¯`·.¸¸.·´¯`·.¸ ><((((º>
Recent AZN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:05:16 PM
- DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates • Business Wire • 05/22/2026 02:16:00 PM
- AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 • Business Wire • 05/22/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 02:15:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 01:42:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 01:36:08 PM
- BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension • Business Wire • 05/18/2026 11:00:00 AM
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer • Business Wire • 05/16/2026 01:52:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/14/2026 11:25:03 AM
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial • Business Wire • 05/14/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:05:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/01/2026 02:23:42 PM
- TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer • Business Wire • 05/01/2026 01:42:00 AM
- Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca • PR Newswire (US) • 04/29/2026 11:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2026 11:23:24 AM
- AstraZeneca results: Q1 2026 • Business Wire • 04/29/2026 11:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/28/2026 03:32:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/28/2026 11:31:55 AM
- BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older • Business Wire • 04/28/2026 11:00:00 AM
- SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus • Business Wire • 04/27/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/27/2026 10:29:18 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/23/2026 10:10:15 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/21/2026 10:19:06 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/20/2026 11:03:40 AM
- Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD • Business Wire • 04/20/2026 11:00:00 AM
